Kidney Disease News and Research

RSS

Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute liver failure, often a fatal diagnosis.

23 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

19 Sep 2014

Benefits of blood pressure lowering drugs for low risk patients 'still open to question'

Dr Stephen Martin and colleagues argue that this strategy is failing patients and wasting healthcare resources. They call for a re-examination of the threshold and urge clinicians to be cautious about treating low risk patients with blood pressure lowering drugs.

16 Sep 2014

Simple point-of-care testing device provides more rapid diagnosis of anemia

A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease.

15 Sep 2014

New collaborative approach could help improve diabetes care in China

Diabetes has become a major public health crisis in China, with an annual projected cost of 360 billion RMB (nearly 35 billion British pounds) by 2030, but a new collaborative approach to care that uses registries and community support could help improve diabetes care, according to a new three-part Series about diabetes in China published in The Lancet Diabetes & Endocrinology.

11 Sep 2014

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology.

11 Sep 2014

Scientists identify how molecular motor essential for human development works

Another mystery of the human body has been solved by scientists who have identified how a molecular motor essential for human development works.

10 Sep 2014

Penn State receives $1.8 million from PCORI to help patients with chronic kidney disease

Penn State College of Medicine has been awarded $1.8 million in research funding from the Patient-Centered Outcomes Research Institute (PCORI).

8 Sep 2014

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

6 Sep 2014

DaVita Kidney Care hosts online Google+ Hangout on Air

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, will host an online Google+ Hangout on Air called "Kidney Diet Tips: Diabetes Edition" on Monday, Sept. 8 at 5:00 p.m. PT/8:00 p.m. ET.

4 Sep 2014

Doctor receives international patents for therapeutic process to remove excess galectin-3

Isaac Eliaz, MD, MS, LAc has been awarded a USA patent as well as additional international patents for a therapeutic process that allows for the removal of excess galectin-3 from the circulatory system using plasmapheresis.

4 Sep 2014

Blood pressure self-management suitable for high-risk patients

Patients with hypertension and high cardiovascular risk can successfully monitor and titrate their own antihypertensive medication, shows research published in JAMA.

1 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Lifestyle intervention shows kidney benefits in diabetic patients

A lifestyle intervention focused on weight loss and increasing physical activity should be considered as additional treatment to prevent advanced kidney disease in overweight or obese people with Type 2 diabetes, say researchers.

28 Aug 2014

Calcium buildup in coronary arteries of chronic kidney disease patients indicates heart disease risk

Calcium buildup in the coronary arteries of chronic kidney disease patients may be a strong indicator of heart disease risk, according to a new study in the Journal of the American Society of Nephrology (JASN).

22 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.